Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains? [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
This compares to the stock's 29.9% gain over the past four weeks. The rise in share price is attributable to the company's progress with its label expansion studies on sol-marketed Pyrukynd. Earlier this month, management reported that the phase III ENERGIZE-T study, evaluating the drug in transfusion-dependent (TD) thalassemia patients, achieved its primary endpoint of statistically significant reduction in transfusion burden. Earlier this year in January, Agios reported positive results from the late-stage ENERGIZE study results, which evaluated Pyrukynd in non-transfusion-dependent (NTD) thalassemia patients. This study also achieved its primary endpoint of hemoglobin response along with lower levels of fatigue. The above results bolster Agios' plans to seek label expansion for Pyrukynd across all thalassemia sub-types before the end of this year. If approved, a commercial launch in this indication is expected next year. The drug is currently approved to treat adults with pyr
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024GlobeNewswire
- Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D. [Yahoo! Finance]Yahoo! Finance
- Is Agios Pharmaceuticals, Inc. (AGIO) a Good Addition to Your Portfolio Now? [Yahoo! Finance]Yahoo! Finance
- Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of VorasidenibGlobeNewswire
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
AGIO
Earnings
- 8/1/24 - Miss
AGIO
Sec Filings
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- 8/12/24 - Form 4
- AGIO's page on the SEC website